• Profile
Close

Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders

Autoimmunity Reviews Dec 01, 2017

Tudesq JJ, et al. - This study offers information regarding the clinical and microbiological features and outcome of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. Based on the findings, it was concluded that rituximab-related infectious events can be extremely severe, especially in patients immunocompromised by several other drugs. The focus of further explorations should be the group with life-threatening polymicrobial infections.

Methods

  • The medical records of patients treated with rituximab in an internal medicine department of a tertiary hospital between 2007 and 2015 were retrospectively analyzed, and all iE after this therapy were identified.
  • Using the Common Terminological Criteria of Adverse Events (version 4.3) definitions, events’ severity was evaluated.

Results

  • A total of 101 patients were treated with rituximab, of these, 228 IE were identified in 74 (73.3%) (median follow-up 30.4 months).
  • Either autoimmune disease (AID) (52.5% of patients), or monoclonal hematological disease (MHD) (47.5%) indicated rituximab.
  • Findings revealed that patients received an overall median number of 5 rituximab infusions [interquartile range: 4-8], representing a cumulative dose of 4340mg [2620-6160].
  • The occurrence of IE after last rituximab infusion was reported after 3.1 months [0.7-9.4].
  • Researchers found that, respectively, IE were severe in 28.1% of cases in patients treated for AID vs 58.0% in patients treated for MHD (p < 0.001), due to opportunistic pathogens in 7.8% vs 11.0% (p=0.49) and fatal in 4.7% vs 13.0% (p=0.044).
  • Polymicrobial infection (p < 0.001), monoclonal hematological disease (p=0.035), use of steroids over 10mg/d within the last two weeks (p=0.003), and rituximab cumulative dose (p < 0.001) were found to be associated with mortality.
  • In addition, a group of 10 patients (9.9%) was identified, exhibiting life-threatening, polymicrobial, and opportunistic infections constituting a ‘catastrophic infectious syndrome’, which was lethal in 7 cases.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay